GLP-1 Receptor Agonists in Cardiometabolic Syndrome

As demonstrated in key trials, Robert A. Gabbay, MD, PhD, remarks on the potential benefits of using glucagon-like peptide-1 receptor agonists in the treatment of patients with diabetes who are at risk for cardiovascular events.